Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

436
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
436
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

400
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
400
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

683
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
683
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

387
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
387
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

417
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
417
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

274
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
274

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GERD management in neonatal ICU infants: study protocol for a randomized controlled trial comparing maturation, added rice starch formula and proton pump inhibitors.

BMC pediatrics·2026
Same author

Rumination syndrome and eosinophilic esophagitis in children: Defining the relationship.

Journal of pediatric gastroenterology and nutrition·2026
Same author

The rumination severity index: Development and evaluation of a scoring tool for rumination syndrome.

Journal of pediatric gastroenterology and nutrition·2026
Same author

Partial Ear Reconstruction Using Septal Cartilage Graft and Skin Expansion.

The Journal of craniofacial surgery·2026
Same author

International Forum on Visceral Myopathy 2024: Advances in the Knowledge of the Disease.

Neurogastroenterology and motility·2026
Same author

American Gastroenterological Association-North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Pediatric Functional Constipation Clinical Care Pathway.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Methodological and Reporting Caveats in Evaluating Facility Detection Metrics for Barrett's Esophagus.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Endotype Clustering Contextualizes the Link Between Hepatic Steatosis and High-Risk Coronary Plaque.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Authors' Reply to the Letter by Dr. Toshikuni on Endotype Clustering, Hepatic Steatosis, and Vulnerable Coronary Plaque.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Blue Notes.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
See all related articles

Related Experiment Video

Updated: Nov 9, 2025

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

687

Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term

Marc A Benninga1, Sunny Z Hussain2, Manu R Sood3

  • 1Department of Paediatric Gastroenterology & Nutrition, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, the Netherlands.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|April 10, 2021
PubMed
Summary
This summary is machine-generated.

Lubiprostone did not prove more effective than placebo for treating pediatric functional constipation. However, the drug was well-tolerated, showing a safety profile similar to that observed in adults.

Keywords:
Clinical TrialDefecationIncontinenceStools

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.9K
Author Spotlight: Exploring the Potential of Massage Therapy in Cerebral Palsy Using Animal Models
08:24

Author Spotlight: Exploring the Potential of Massage Therapy in Cerebral Palsy Using Animal Models

Published on: August 11, 2023

2.4K

Related Experiment Videos

Last Updated: Nov 9, 2025

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

687
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.9K
Author Spotlight: Exploring the Potential of Massage Therapy in Cerebral Palsy Using Animal Models
08:24

Author Spotlight: Exploring the Potential of Massage Therapy in Cerebral Palsy Using Animal Models

Published on: August 11, 2023

2.4K

Area of Science:

  • Gastroenterology
  • Pediatric Medicine
  • Clinical Pharmacology

Background:

  • Pediatric functional constipation (PFC) is a prevalent condition in children, posing significant challenges for healthcare providers.
  • Lubiprostone is a medication used to treat constipation, but its efficacy in pediatric populations required further investigation.

Purpose of the Study:

  • To evaluate the efficacy and safety of lubiprostone in children and adolescents diagnosed with pediatric functional constipation.
  • To compare lubiprostone's effectiveness against a placebo in a randomized controlled trial setting.

Main Methods:

  • A phase 3, multicenter, randomized, double-blind, placebo-controlled trial (Study 1) involving 606 patients aged 6-17 years with PFC.
  • Patients received either lubiprostone (12 μg or 24 μg twice daily) or placebo for 12 weeks, with doses adjusted by weight.
  • An open-label extension study (Study 2) followed for participants who completed the initial phase.

Main Results:

  • No statistically significant difference in the overall spontaneous bowel movement (SBM) response rate was found between the lubiprostone and placebo groups (18.5% vs 14.4%, P = .2245).
  • Both 12 μg and 24 μg twice daily doses of lubiprostone were well-tolerated during the double-blind and extension phases.
  • The safety profile of lubiprostone in pediatric patients was consistent with findings from adult studies.

Conclusions:

  • Lubiprostone did not demonstrate statistically significant effectiveness compared to placebo in treating pediatric functional constipation.
  • The safety and tolerability of lubiprostone in children and adolescents were comparable to those observed in adult populations.